Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Nör JE[au]:

Search results

Items: 1 to 50 of 192

1.

Comparative Evaluation of the Cytotoxic and Angiogenic Effects of Minocycline and Clindamycin: An In Vitro Study.

Dubey N, Xu J, Zhang Z, Nör JE, Bottino MC.

J Endod. 2019 Jul;45(7):882-889. doi: 10.1016/j.joen.2019.04.007. Epub 2019 May 24.

PMID:
31133343
2.

Inhibition of Nuclear Factor Kappa B Prevents the Development of Experimental Periapical Lesions.

Kaneko T, Myo Zaw SY, Sueyama Y, Katsube KI, Kaneko R, Nör JE, Okiji T.

J Endod. 2019 Feb;45(2):168-173. doi: 10.1016/j.joen.2018.10.006.

PMID:
30711173
3.

UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.

Warner KA, Oklejas AE, Pearson AT, Zhang Z, Wu W, Divi V, Rodriguez-Ramirez C, Castilho RM, Polverini PJ, Nör JE.

Oral Oncol. 2018 Dec;87:21-28. doi: 10.1016/j.oraloncology.2018.10.012. Epub 2018 Oct 18.

PMID:
30527239
4.

Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.

Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE.

Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi: 10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29.

PMID:
30498096
5.

p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Rodriguez-Ramirez C, Nör JE.

Crit Rev Oncog. 2018;23(3-4):173-187. doi: 10.1615/CritRevOncog.2018027353. Review.

6.

Animal Models for Stem Cell-Based Pulp Regeneration: Foundation for Human Clinical Applications.

Nakashima M, Iohara K, Bottino MC, Fouad AF, Nör JE, Huang GT.

Tissue Eng Part B Rev. 2019 Apr;25(2):100-113. doi: 10.1089/ten.TEB.2018.0194. Epub 2019 Jan 9. Review.

PMID:
30284967
7.

A novel patient-specific three-dimensional drug delivery construct for regenerative endodontics.

Bottino MC, Albuquerque MTP, Azabi A, Münchow EA, Spolnik KJ, Nör JE, Edwards PC.

J Biomed Mater Res B Appl Biomater. 2019 Jul;107(5):1576-1586. doi: 10.1002/jbm.b.34250. Epub 2018 Oct 3.

PMID:
30281899
8.

Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review.

Curtarelli RB, Gonçalves JM, Dos Santos LGP, Savi MG, Nör JE, Mezzomo LAM, Rodríguez Cordeiro MM.

Stem Cell Rev Rep. 2018 Dec;14(6):769-784. doi: 10.1007/s12015-018-9839-4.

PMID:
30076557
9.

Signals in Stem Cell Differentiation on Fluorapatite-Modified Scaffolds.

Guo T, Cao G, Li Y, Zhang Z, Nör JE, Clarkson BH, Liu J.

J Dent Res. 2018 Nov;97(12):1331-1338. doi: 10.1177/0022034518788037. Epub 2018 Jul 11.

PMID:
29995454
10.

FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin.

McDermott SC, Rodriguez-Ramirez C, McDermott SP, Wicha MS, Nör JE.

Oncotarget. 2018 May 18;9(38):25148-25165. doi: 10.18632/oncotarget.25358. eCollection 2018 May 18.

11.

Head and Neck Cancer in the New Era of Precision Medicine.

Nör JE, Gutkind JS.

J Dent Res. 2018 Jun;97(6):601-602. doi: 10.1177/0022034518772278. No abstract available.

PMID:
29771196
12.

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL.

Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. doi: 10.1158/1078-0432.CCR-17-2807. Epub 2018 May 16.

13.

Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.

Wagner VP, Martins MD, Martins MAT, Almeida LO, Warner KA, Nör JE, Squarize CH, Castilho RM.

Sci Rep. 2018 Feb 1;8(1):2065. doi: 10.1038/s41598-018-20345-w.

14.

Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis.

Hill EE, Kim JK, Jung Y, Neeley CK, Pienta KJ, Taichman RS, Nor JE, Baker JR Jr, Krebsbach PH.

J Cell Biochem. 2018 Nov;119(10):8074-8083. doi: 10.1002/jcb.26727. Epub 2018 Jun 22.

PMID:
29380900
15.

A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment.

Nazari F, Pearson AT, Nör JE, Jackson TL.

PLoS Comput Biol. 2018 Jan 19;14(1):e1005920. doi: 10.1371/journal.pcbi.1005920. eCollection 2018 Jan.

16.

Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels.

Kim HS, Chen YC, Nör F, Warner KA, Andrews A, Wagner VP, Zhang Z, Zhang Z, Martins MD, Pearson AT, Yoon E, Nör JE.

Oncotarget. 2017 Nov 1;8(59):100339-100352. doi: 10.18632/oncotarget.22225. eCollection 2017 Nov 21.

17.

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review.

Chisini LA, Conde MCM, Grazioli G, Martin ASS, Carvalho RV, Nör JE, Demarco FF.

Braz Dent J. 2017 Nov-Dec;28(6):657-668. doi: 10.1590/0103-6440201701646. Review.

18.

Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ, Morgan TM, Keller ET, Nör JE, Shea LD, McCauley LK.

J Clin Invest. 2018 Jan 2;128(1):248-266. doi: 10.1172/JCI92466. Epub 2017 Nov 27.

19.

Advanced Scaffolds for Dental Pulp and Periodontal Regeneration.

Bottino MC, Pankajakshan D, Nör JE.

Dent Clin North Am. 2017 Oct;61(4):689-711. doi: 10.1016/j.cden.2017.06.009. Review.

20.

Lipoprotein Receptor-related Protein 6 Signaling is Necessary for Vasculogenic Differentiation of Human Dental Pulp Stem Cells.

Silva GO, Zhang Z, Cucco C, Oh M, Camargo CHR, Nör JE.

J Endod. 2017 Sep;43(9S):S25-S30. doi: 10.1016/j.joen.2017.06.006. Epub 2017 Aug 1.

21.

Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.

Birkeland AC, Burgin SJ, Yanik M, Scott MV, Bradford CR, McHugh JB, McLean SA, Sullivan SE, Nor JE, McKean EL, Brenner JC.

J Neurol Surg B Skull Base. 2017 Aug;78(4):346-352. doi: 10.1055/s-0037-1601320. Epub 2017 Mar 27.

22.

Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.

Birkeland AC, Foltin SK, Michmerhuizen NL, Hoesli RC, Rosko AJ, Byrd S, Yanik M, Nor JE, Bradford CR, Prince ME, Carey TE, McHugh JB, Spector ME, Brenner JC.

Oral Oncol. 2017 May;68:5-8. doi: 10.1016/j.oraloncology.2017.02.025. Epub 2017 Mar 10.

23.

Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence.

Almeida LO, Guimarães DM, Martins MD, Martins MAT, Warner KA, Nör JE, Castilho RM, Squarize CH.

Stem Cell Res. 2017 May;21:94-105. doi: 10.1016/j.scr.2017.04.003. Epub 2017 Apr 8. No abstract available.

24.

Dental Pulp Tissue Regeneration Using Dental Pulp Stem Cells Isolated and Expanded in Human Serum.

Piva E, Tarlé SA, Nör JE, Zou D, Hatfield E, Guinn T, Eubanks EJ, Kaigler D.

J Endod. 2017 Apr;43(4):568-574. doi: 10.1016/j.joen.2016.11.018. Epub 2017 Feb 16.

25.

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.

Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nör F, Wagner VP, Vargas PA, Wicha MS, Hurt EM, Hollingsworth RE, Tice DA, Nör JE.

Clin Cancer Res. 2017 May 15;23(10):2516-2527. doi: 10.1158/1078-0432.CCR-16-1834. Epub 2016 Oct 25.

26.

A scoping review of root canal revascularization: relevant aspects for clinical success and tissue formation.

Conde MCM, Chisini LA, Sarkis-Onofre R, Schuch HS, Nör JE, Demarco FF.

Int Endod J. 2017 Sep;50(9):860-874. doi: 10.1111/iej.12711. Epub 2016 Dec 3. Review.

27.

Immunohistochemical Expression of TGF-β1 and Osteonectin in engineered and Ca(OH)2-repaired human pulp tissues.

Chisini LA, Conde MC, Alcázar JC, Silva AF, Nör JE, Tarquinio SB, Demarco FF.

Braz Oral Res. 2016 Oct 10;30(1):e93. doi: 10.1590/1807-3107BOR-2016.vol30.0093.

28.

Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axis.

Wagner VP, Martins MA, Martins MD, Warner KA, Webber LP, Squarize CH, Nör JE, Castilho RM.

Oncotarget. 2016 Nov 8;7(45):73032-73044. doi: 10.18632/oncotarget.12195.

29.

Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.

Nör F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI, Sant'Ana Filho M, Wang S, Nör JE.

Clin Cancer Res. 2017 Feb 15;23(4):1036-1048. doi: 10.1158/1078-0432.CCR-16-1235. Epub 2016 Aug 22.

30.

Pluripotency of Stem Cells from Human Exfoliated Deciduous Teeth for Tissue Engineering.

Rosa V, Dubey N, Islam I, Min KS, Nör JE.

Stem Cells Int. 2016;2016:5957806. doi: 10.1155/2016/5957806. Epub 2016 May 30. Review.

31.

Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells.

Guimarães DM, Almeida LO, Martins MD, Warner KA, Silva AR, Vargas PA, Nunes FD, Squarize CH, Nör JE, Castilho RM.

Oncotarget. 2016 Jul 5;7(27):42447-42460. doi: 10.18632/oncotarget.9884.

32.

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.

Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE.

Neoplasia. 2016 May;18(5):273-281. doi: 10.1016/j.neo.2016.03.004. Epub 2016 Apr 15.

33.

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.

Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.

34.

Modeling head and neck cancer stem cell-mediated tumorigenesis.

Pearson AT, Jackson TL, Nör JE.

Cell Mol Life Sci. 2016 Sep;73(17):3279-89. doi: 10.1007/s00018-016-2226-x. Epub 2016 May 5. Review.

35.

Simvastatin inhibits the expression of inflammatory cytokines and cell adhesion molecules induced by LPS in human dental pulp cells.

Jung JY, Woo SM, Kim WJ, Lee BN, Nör JE, Min KS, Choi CH, Koh JT, Lee KJ, Hwang YC.

Int Endod J. 2017 Apr;50(4):377-386. doi: 10.1111/iej.12635. Epub 2016 Apr 15.

36.

Autophagy Modulates Cell Mineralization on Fluorapatite-Modified Scaffolds.

Li Y, Guo T, Zhang Z, Yao Y, Chang S, Nör JE, Clarkson BH, Ni L, Liu J.

J Dent Res. 2016 Jun 1;95(6):650 – 656. Epub 2016 Mar 9.

PMID:
26961490
37.

Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma.

Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE.

Clin Cancer Res. 2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2.

38.

Isolation and Characterization of Cancer Stem Cells from Primary Head and Neck Squamous Cell Carcinoma Tumors.

Kim HS, Pearson AT, Nör JE.

Methods Mol Biol. 2016;1395:241-9. doi: 10.1007/978-1-4939-3347-1_14.

39.

Wnt/β-Catenin Signaling Determines the Vasculogenic Fate of Postnatal Mesenchymal Stem Cells.

Zhang Z, Nör F, Oh M, Cucco C, Shi S, Nör JE.

Stem Cells. 2016 Jun;34(6):1576-87. doi: 10.1002/stem.2334. Epub 2016 Mar 11.

40.

Patient-derived xenograft (PDX) tumors increase growth rate with time.

Pearson AT, Finkel KA, Warner KA, Nör F, Tice D, Martins MD, Jackson TL, Nör JE.

Oncotarget. 2016 Feb 16;7(7):7993-8005. doi: 10.18632/oncotarget.6919.

41.

The Perivascular Niche and Self-Renewal of Stem Cells.

Oh M, Nör JE.

Front Physiol. 2015 Dec 2;6:367. doi: 10.3389/fphys.2015.00367. eCollection 2015. Review.

42.

Craniofacial Stem Cells in Health and Disease.

Klein OD, Nör JE.

J Dent Res. 2015 Nov;94(11):1485-6. doi: 10.1177/0022034515608368. No abstract available.

PMID:
26494794
43.

ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas.

Adams A, Warner K, Pearson AT, Zhang Z, Kim HS, Mochizuki D, Basura G, Helman J, Mantesso A, Castilho RM, Wicha MS, Nör JE.

Oncotarget. 2015 Sep 29;6(29):26633-50. doi: 10.18632/oncotarget.5782.

44.

Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.

Mochizuki D, Adams A, Warner KA, Zhang Z, Pearson AT, Misawa K, McLean SA, Wolf GT, Nör JE.

Oncotarget. 2015 Sep 8;6(26):22822-35.

45.

The dental pulp stem cell niche based on aldehyde dehydrogenase 1 expression.

Machado CV, Passos ST, Campos TM, Bernardi L, Vilas-Bôas DS, Nör JE, Telles PD, Nascimento IL.

Int Endod J. 2016 Aug;49(8):755-63. doi: 10.1111/iej.12511. Epub 2015 Aug 21.

46.

BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma.

Acasigua GA, Warner KA, Nör F, Helman J, Pearson AT, Fossati AC, Wang S, Nör JE.

Oral Oncol. 2015 Sep;51(9):839-47. doi: 10.1016/j.oraloncology.2015.06.004. Epub 2015 Jun 26.

47.

Stem cell-based pulp tissue engineering: variables enrolled in translation from the bench to the bedside, a systematic review of literature.

Conde MC, Chisini LA, Demarco FF, Nör JE, Casagrande L, Tarquinio SB.

Int Endod J. 2016 Jun;49(6):543-50. doi: 10.1111/iej.12489. Epub 2015 Jul 20. Review.

PMID:
26101143
48.

Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies.

Kamocki K, Nör JE, Bottino MC.

Arch Oral Biol. 2015 Aug;60(8):1131-7. doi: 10.1016/j.archoralbio.2015.05.002. Epub 2015 May 16.

49.

Influence of poly-L-lactic acid scaffold's pore size on the proliferation and differentiation of dental pulp stem cells.

Conde CM, Demarco FF, Casagrande L, Alcazar JC, Nör JE, Tarquinio SB.

Braz Dent J. 2015 Mar-Apr;26(2):93-8. doi: 10.1590/0103-6440201300032. Epub 2015 Apr 1.

50.

Dental pulp stem cell responses to novel antibiotic-containing scaffolds for regenerative endodontics.

Kamocki K, Nör JE, Bottino MC.

Int Endod J. 2015 Dec;48(12):1147-56. doi: 10.1111/iej.12414. Epub 2014 Dec 24.

Supplemental Content

Support Center